Tesla Defies Musk's No-Endorsement Rule by Signing Korean Olympian Kim Ye-ji 
IMF Urges Japan to Balance Budget as Bank of Japan Signals Gradual Rate Hikes 
Tesla and Uber Unveil $2,000 Incentive Program for Model 3 and Model Y Drivers 
South Korea's Export Growth Falls to Seven-Month Low Amid Global Demand Concerns 
China’s DeepRoute.ai Secures $100M to Lead Autonomous Driving, Eyes 200,000-Car Rollout by 2025 
New Home Prices in China Rise Amid Market Recovery Efforts 
Nio to Launch First Hybrid Model in 2026: A Strategic Move for Global Markets 
Moldova’s Pivotal Presidential Runoff: A Choice Between East and West 
Crypto Markets Could Swing Wildly if US Election Results Remain Unclear, Analysts Say 
Dogecoin Creator Backs X Merch Payment Move, Sparking Speculation of a 27% DOGE Rally 
Gold Prices Surge Amid Election Uncertainty and Fed Speculation 
Commodity Trading Advisors Favor U.S. Stocks, Dollar, and Gold Ahead of Presidential Elections 
Samsung Defies NVIDIA Fall-Out Rumors, Eyes HBM3E Integration in AI Accelerators Next Quarter 
Kamala Harris Leads Trump in New Iowa Poll, Driven by Women Voters 
Why a Republican Win Could Trigger Euro and French Bond Sell-Offs: Insights from Charles Gave 
Westpac's Profit Declines Amid Rising Costs, But Dividend Boosts Investor Confidence 
Trump Pledges 100% Tariff on Stellantis for Potential U.S. Job Relocation to Mexico 
Samsung Biologics and Novartis International AG signed a contract manufacturing organization deal, and this was announced on Tuesday, June 7. The deal is worth $81 million.
According to The Korea Herald, the South Korean biotech company signed an intent letter for the CMO with the Swiss multinational pharmaceutical corporation. The agreement was announced via Samsung Biologics’ regulatory filing that also revealed that the companies signed the initial contract late last week.
Based on the report, the amount of the contract is equivalent to 6.41% of Samsung Biologics’ annual sales last year, which reached KRW1.57 trillion or around $1.25 billion. Then again, it was not mentioned which of Novartis’ biopharmaceutical products Samsung Biologics is producing under the CMO agreement.
The Korean biotech firm said that it would be releasing more deals in the future after both parties signed the main contract for their CMO partnership. The collab is said to be the first time Samsung Biologics is securing a deal from the Swiss pharmaceutical company.
“The letter of intent was the first contract between the two firms,” an official of Samsung Biologics stated. “We look forward to continuing to have cooperative relations through this deal in the future.”
The Korea Economic Daily reported that the latest deal increased Samsung Biologics’ total for CMO contracts to $400 million. The company has so far won orders from other multinational pharma firms such as GSK plc that is formerly known as GlaxoSmithKline plc, and Eli Lilly & Co. this year. In comparison, the firm was able to secure $1 billion worth of CMO contracts in 2021.
The South Korean CMO drugmaker obtained contracts from the top pharmaceutical firms in the world, including Bristol Myers Squibb, Roche, Johnson & Johnson, and Merck & Co. It was added that Samsung Biologics also has a contract with Gilead Sciences Inc. in the US.
Meanwhile, Samsung Biologics has been mostly manufacturing antibody treatments recently instead of cell-gene therapy (CGT). It has built up production facilities to make the drug substance for the messenger ribonucleic acid (mRNA)-based COVID-19 vaccines in its plant.
